The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: A pilot randomized, double-blind, placebo-controlled trial

Iranian Journal of Pharmaceutical Research

Volumn 14, Issue 2, 2015, Pages 479-486

  Mirzabeigi, Parastoo ^a   Mohammadpour, Amir Hooshang ^b   Salarifar, Mojtaba ^c   Gholami, Kheirollah ^a   Mojtahedzadeh, Mojtaba ^a   Javadi, Mohammad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood glucose; Coronary artery disease; Curcumin; Hs CRP; Lipid profile

Indexed keywords

C REACTIVE PROTEIN; CURCUMIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 84923031275     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wang TJ. New cardiovascular risk factors exist, but are they clinically useful? Eur. Heart J. (2008) 29: 441-444.
2. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M and Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis (2003) 167: 73-79.
3. Libby P, Ridker PM and Maseri A. Inflammation and atherosclerosis. Circulation (2002) 105: 1135-1143.
4. Nasiripour S, Gholami Kh, Mousavi S, Mohagheghi A, Radfar M, Abdollahi M, Khazaeipour Z and Mojtahedzadeh M. Comparison of the effects of enoxaparin and heparin on inflammatory biomarkers in patients with st-segment elevated myocardial infarction: a prospective open label pilot clinical trial. Iran. J. Pharm. Res. (2014) 13: 583-590.
5. Acharjee S, Qin J, Murphy SA, McCabe C and Cannon CP. Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 Trial). Am. J. Cardiol. (2010) 105: 619-623.
6. Kohli K, Ali J, Ansari MJ and Raheman Z. Curcumin: a natural antiinflammatory agent. Indian J. Pharmacol. (2005) 3: 141-147.
7. Kapakos G, Youreva V and Srivastava A. Cardiovascular protection by curcumin: molecular aspects. Indian J. Biochem. Biophys (2012) 49: 306-315.
8. Goel A, Kunnumakkara AB and Aggarwal BB. Curcumin as curecumin: from kitchen to clinic. Biochem. Pharmacol. (2008) 75: 787-809.
9. Hamed OA, Mehdawi N, Taha AA, Hamed EM, Al-Nuri MA and Hussein AS. Synthesis and antibacterial activity of novel curcumin derivatives containing heterocyclic moiety. Iran. J. Pharm. Res. (2013) 12: 47-56.
10. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, James Crowell J, Rock CL and Brenner DE. Dose escalation of a curcuminoid formulation. BMC. Compl. Altern. Med. (2006) 6: 10-13.
11. Quiles JL, Aguilera C, Mesa MD, Ramirez-Tortosa MC, Baro L and Gil A. An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors (1998) 8: 51-57.
12. Wongcharoen W and Phrommintikul A. The protective role of curcumin in cardiovascular diseases Int. J. Cardiol. (2009) 133: 145-151.
13. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E and Gil A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis (1999) 147: 371-378.
14. Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S and Korbut R. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J. Physiol. Pharmacol. (2005) 56: 627-635.
15. Kim M and Kim Y. Hypocholesterolemic effects of curcumin via up-regulation of cholesterol 7a-hydroxylase in rats fed a high fat diet. Nutr. Res. Pract. (2010) 4: 191-195.
16. Soni KB and Kuttan R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J. Physiol. Pharmacol. (1992) 36: 273-275.
17. Ramirez-Bosca A, Soler A, Carrion MA, Mira DP, Zapata JP, Diaz J, Bernd A, Almagro EQ and Miquel J. Anhydroalcoholic extract of curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech. Ageing. Dev. (2000) 119: 41-47.
18. Baum L, Cheunga SK, Mok V, Lamb CW, Leung V, Hui E, Ng C, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng KF, Fong C, Lee JS, Chanh MH, Szeto S, Lui V, Tsoh J, Kwok T, Chang IH and Lam CW. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol. Res. (2007) 56: 509-514.
19. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB and Ernie S. The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta. Med. Indones (2008) 40: 201-210.
20. Pungcharoenkul K and Thongnopnua P. Effect of different curcuminoid supplement dosages on total in-vivo antioxidant capacity and cholesterol levels of healthy human subjects. Phytother. Res. (2011) 25: 1721-1726.
21. Feng D, Ohlsson L and Duan R. Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression. Lipids Health Dis. (2010) 9: 40.
22. Mahesh T, Sri Balasubashini MM and Menon VP. Photo-irradiated curcumin supplementation in streptozotocin-induced diabetic rats: effect on lipid peroxidation. Therapie. (2004) 59: 639-644.
23. Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa M, Takahashi K, Kawada T, Nakagawa K and Kitahara M. Hypoglycemic effects of turmeric (Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. Biol. Pharm. Bull. (2005) 28: 937-939.
24. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K and Kitahara M. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J. Agric. Food Chem. (2005) 53: 959-963.
25. Best L, Elliott AC and Brown PD. Curcumin induces electrical activity in rat pancreatic b-cells by activating the volume- regulated anion channel. Biochem. Pharmacol. (2007) 73: 1768-1775.
26. Seo K, Choi M, Jung U, Kim H, Yeo J, Jeon S and Lee M. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol. Nutr. Food Res. (2008) 52: 1-10.
27. Yeh CH, Chen TP, Wu YC, Lin YM and Jing Lin P. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/ reperfusion. J. Surg. Res. (2005) 125: 109-116.
28. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Saito T, Manabe I, Imai Y and Nagai R. C-reactive protein induces VCAM-1 gene expression through NF-kappaB activation in vascular endothelial cells. Atherosclerosis (2006) 185: 39-46.
29. Biswas S and Rahman I. Modulation of steroid activity in chronic inflammation: A novel anti-inflammatory role for curcumin. Mol. Nutr. Food Res. (2008) 52: 987-994.
30. Holt PR, Katz S and Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig. Dis. Sci. (2005) 50: 2191-193.
31. Deodhar SD, Sethi R and Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res. (1980) 71: 632-634.
32. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T and Koide Y. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, doubleblind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2006) 4: 1502-1506.
33. Bundy R, Walker AF, Middleton RW and Booth J. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J. Altern. Compl. Med. (2004) 10: 1015-1008.
34. Satoskar RR, Shah SJ and Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int. J. Clin. Pharmacol. Ther. Toxicol. (1986) 24: 651-654.
35. Lal B, Kapoor AK, Aggrawal PK, Asthana OP and Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother. Res. (2000) 14: 443-447.
36. Sharma RA, Steward WP and Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv. Exp. Med. Biol. (2007) 595: 453-470.